[PDF][PDF] Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
J Hamanishi, M Mandai, T Ikeda, M Minami… - Journal of Clinical …, 2015 - researchmap.jp
Journal of Clinical Oncology, 2015•researchmap.jp
Purpose Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T
cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti–PD-1
antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of
nivolumab in patients with platinum-resistant ovarian cancer.
cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti–PD-1
antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of
nivolumab in patients with platinum-resistant ovarian cancer.
Purpose
Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T cells, binds to PD-1 ligand and regulates antitumor immunity. Nivolumab is an anti–PD-1 antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of nivolumab in patients with platinum-resistant ovarian cancer.
researchmap.jp